BR0308071A - Inibidores da protéina farnesil transferase como agentes antitumores - Google Patents
Inibidores da protéina farnesil transferase como agentes antitumoresInfo
- Publication number
- BR0308071A BR0308071A BR0308071-4A BR0308071A BR0308071A BR 0308071 A BR0308071 A BR 0308071A BR 0308071 A BR0308071 A BR 0308071A BR 0308071 A BR0308071 A BR 0308071A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- protein inhibitors
- formula
- farnesyl transferase
- transferase protein
- Prior art date
Links
- 229940121649 protein inhibitor Drugs 0.000 title abstract 2
- 239000012268 protein inhibitor Substances 0.000 title abstract 2
- 102000007317 Farnesyltranstransferase Human genes 0.000 title 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 title 1
- 230000002738 anti-smoking effect Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000004357 Transferases Human genes 0.000 abstract 2
- 108090000992 Transferases Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229950008696 farnesil Drugs 0.000 abstract 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"INIBIDORES DA PROTEìNA FARNESIL TRANSFERASE COMO AGENTES ANTITUMORES". São apresentados novos compostos tricíclicos representados pela fórmula (1.0) e um sal ou solvato farmaceuticamente aceitável destes. Os compostos são úteis para a inibição da proteína farnesil transferase. Também são apresentados composições farmacêuticas compreendendo os compostos de fórmula 1.0. Da mesma forma são apresentados métodos de tratamento de câncer usando os compostos de fórmula 1.0.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/085,896 US20030229099A1 (en) | 2000-08-30 | 2002-02-27 | Novel farnesyl protein transferase inhibitors as antitumor agents |
US10/325,896 US7342016B2 (en) | 2000-08-30 | 2002-12-19 | Farnesyl protein transferase inhibitors as antitumor agents |
PCT/US2003/005479 WO2003072549A1 (en) | 2002-02-27 | 2003-02-25 | Farnesyl protein transferase inhibitors as antitumor agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0308071A true BR0308071A (pt) | 2004-12-21 |
Family
ID=27767345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0308071-4A BR0308071A (pt) | 2002-02-27 | 2003-02-25 | Inibidores da protéina farnesil transferase como agentes antitumores |
Country Status (19)
Country | Link |
---|---|
US (1) | US7342016B2 (pt) |
EP (1) | EP1492772A1 (pt) |
JP (1) | JP2005525356A (pt) |
KR (1) | KR20040098004A (pt) |
CN (1) | CN100537542C (pt) |
AR (1) | AR039557A1 (pt) |
AU (1) | AU2003215389B2 (pt) |
BR (1) | BR0308071A (pt) |
CA (1) | CA2477328A1 (pt) |
CO (1) | CO5611194A2 (pt) |
IL (1) | IL163673A0 (pt) |
MX (1) | MXPA04008303A (pt) |
NO (1) | NO20044053L (pt) |
NZ (1) | NZ534809A (pt) |
PE (1) | PE20031038A1 (pt) |
PL (1) | PL372335A1 (pt) |
RU (1) | RU2004128465A (pt) |
TW (1) | TW200303867A (pt) |
WO (1) | WO2003072549A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2526085A1 (en) * | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Treatment with anti-vegf antibodies |
US7557107B2 (en) * | 2003-08-07 | 2009-07-07 | Schering Coporation | Farnesyl protein transferase inhibitors as antitumor agents |
CA2568524A1 (en) * | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
SI1753764T1 (sl) | 2004-06-09 | 2009-02-28 | Glaxo Group Ltd | Derivati pirolopiridina |
CA2591123A1 (en) | 2004-12-14 | 2006-06-22 | Schering Corporation | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases |
JP2008524337A (ja) * | 2004-12-21 | 2008-07-10 | シェーリング コーポレイション | 抗腫瘍剤としての新規なファルネシルタンパク質トランスフェラーゼ阻害剤 |
CN101400656A (zh) * | 2006-01-19 | 2009-04-01 | 先灵公司 | 作为法呢基蛋白转移酶抑制剂的哌嗪衍生物 |
WO2008054598A2 (en) * | 2006-09-29 | 2008-05-08 | Schering Corporation | Panel of biomarkers for prediction of fti efficacy |
US20080248033A1 (en) * | 2006-12-19 | 2008-10-09 | Genentech, Inc. | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
US8629135B2 (en) | 2008-07-14 | 2014-01-14 | Queen's University At Kingston | Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer |
EP2408449A4 (en) | 2009-03-18 | 2012-08-08 | Univ Leland Stanford Junior | METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS |
US9187454B2 (en) * | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
US9227962B2 (en) | 2013-03-13 | 2016-01-05 | Boston Biomedical, Inc. | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative |
CN105777646A (zh) * | 2016-04-08 | 2016-07-20 | 西南科技大学 | 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法 |
CN111454329A (zh) * | 2020-04-07 | 2020-07-28 | 哈尔滨师范大学 | 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法 |
CN115385892A (zh) * | 2021-10-28 | 2022-11-25 | 天津市昕晨投资发展有限公司 | 地氯雷他定衍生物、其制备方法及其用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4826853A (en) | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
US5393890A (en) | 1988-06-02 | 1995-02-28 | Ajinomoto Co., Inc. | Piperidine derivatives and hypotensives containing the same |
EP0552245A1 (en) | 1990-10-10 | 1993-07-28 | Schering Corporation | Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use |
GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
US5643909A (en) | 1993-04-19 | 1997-07-01 | Syntex (U.S.A.) Inc. | 10,11-Methanodibenzosuberane derivatives |
US6075025A (en) * | 1993-10-15 | 2000-06-13 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
US5721236A (en) | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
AU730194B2 (en) * | 1995-12-22 | 2001-03-01 | Merck Sharp & Dohme Corp. | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases |
CA2265764A1 (en) * | 1996-09-13 | 1998-03-19 | Schering Corporation | Tricyclic compounds useful as fpt inhibitors |
US6071907A (en) | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
DE69731544T2 (de) | 1996-09-13 | 2005-10-27 | Schering Corp. | Trizyklische antitumor verbindungen mit farnesyl protein transferase inhibierender wirkung |
US5861395A (en) * | 1996-09-13 | 1999-01-19 | Schering Corporation | Compounds useful for inhibition of farnesyl proteins transferase |
GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
WO1998057960A1 (en) | 1997-06-17 | 1998-12-23 | Schering Corporation | Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase |
KR20010013881A (ko) | 1997-06-17 | 2001-02-26 | 둘락 노먼 씨. | 파네실 단백질 전이효소의 신규한 n-치환된 우레아 억제제 |
SK283820B6 (sk) | 1997-06-17 | 2004-02-03 | Schering Corporation | Tricyklická amidová zlúčenina, farmaceutický prostriedok s jej obsahom a jej použitie |
ZA985218B (en) | 1997-06-17 | 1998-12-15 | Schering Corp | Novel sulfonamide inhibitors of farnesyl-protein transferase |
US5925648A (en) | 1997-07-29 | 1999-07-20 | Schering Corporation | Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase |
CA2354774C (en) | 1998-12-18 | 2009-05-26 | Schering Corporation | Farnesyl protein transferase inhibitors |
JP2002533336A (ja) | 1998-12-18 | 2002-10-08 | シェーリング コーポレイション | 三環式ファルネシルタンパク質トランスフェラーゼインヒビター |
WO2001045740A2 (en) * | 1999-12-22 | 2001-06-28 | The Government Of The United States, Department Of Health And Human Services | Compositions and methods for treatment of breast cancer |
SI1255537T1 (sl) | 2000-02-04 | 2006-10-31 | Janssen Pharmaceutica Nv | Inhibitorji farnezil protein transferaze za zdravljenje raka dojk |
AR033680A1 (es) | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
CN1849122A (zh) * | 2001-12-03 | 2006-10-18 | 先灵公司 | Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途 |
US7557107B2 (en) * | 2003-08-07 | 2009-07-07 | Schering Coporation | Farnesyl protein transferase inhibitors as antitumor agents |
-
2002
- 2002-12-19 US US10/325,896 patent/US7342016B2/en not_active Expired - Fee Related
-
2003
- 2003-02-25 MX MXPA04008303A patent/MXPA04008303A/es unknown
- 2003-02-25 BR BR0308071-4A patent/BR0308071A/pt not_active IP Right Cessation
- 2003-02-25 NZ NZ534809A patent/NZ534809A/en not_active IP Right Cessation
- 2003-02-25 RU RU2004128465/04A patent/RU2004128465A/ru not_active Application Discontinuation
- 2003-02-25 AU AU2003215389A patent/AU2003215389B2/en not_active Ceased
- 2003-02-25 CN CNB038047209A patent/CN100537542C/zh not_active Expired - Fee Related
- 2003-02-25 EP EP03711214A patent/EP1492772A1/en not_active Withdrawn
- 2003-02-25 WO PCT/US2003/005479 patent/WO2003072549A1/en active Application Filing
- 2003-02-25 PL PL03372335A patent/PL372335A1/xx not_active Application Discontinuation
- 2003-02-25 AR ARP030100602A patent/AR039557A1/es unknown
- 2003-02-25 IL IL16367303A patent/IL163673A0/xx unknown
- 2003-02-25 JP JP2003571255A patent/JP2005525356A/ja active Pending
- 2003-02-25 KR KR10-2004-7013310A patent/KR20040098004A/ko active IP Right Grant
- 2003-02-25 CA CA002477328A patent/CA2477328A1/en not_active Abandoned
- 2003-02-26 TW TW092104046A patent/TW200303867A/zh unknown
- 2003-02-26 PE PE2003000190A patent/PE20031038A1/es not_active Application Discontinuation
-
2004
- 2004-08-13 CO CO04079404A patent/CO5611194A2/es not_active Application Discontinuation
- 2004-09-24 NO NO20044053A patent/NO20044053L/no unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003215389A1 (en) | 2003-09-09 |
CA2477328A1 (en) | 2003-09-04 |
AU2003215389B2 (en) | 2007-10-18 |
CO5611194A2 (es) | 2006-02-28 |
MXPA04008303A (es) | 2005-11-23 |
NZ534809A (en) | 2007-12-21 |
US7342016B2 (en) | 2008-03-11 |
TW200303867A (en) | 2003-09-16 |
JP2005525356A (ja) | 2005-08-25 |
NO20044053L (no) | 2004-11-26 |
KR20040098004A (ko) | 2004-11-18 |
PE20031038A1 (es) | 2004-01-10 |
CN100537542C (zh) | 2009-09-09 |
AR039557A1 (es) | 2005-02-23 |
RU2004128465A (ru) | 2005-09-27 |
WO2003072549A1 (en) | 2003-09-04 |
PL372335A1 (en) | 2005-07-11 |
IL163673A0 (en) | 2005-12-18 |
EP1492772A1 (en) | 2005-01-05 |
CN1630641A (zh) | 2005-06-22 |
US20040122018A1 (en) | 2004-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066349A (es) | Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales | |
BR0308071A (pt) | Inibidores da protéina farnesil transferase como agentes antitumores | |
LTC1934174I2 (lt) | Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui | |
MXPA05007352A (es) | Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion. | |
BR0312408A (pt) | Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap) | |
BR0206955A (pt) | Ligantes de receptores de canabinóides | |
BRPI0407618A (pt) | derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização | |
TW200613243A (en) | Novel compounds | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
SE0302192D0 (sv) | Novel compounds | |
BRPI0608216A2 (pt) | agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo | |
ATE372995T1 (de) | Benzo(b)(1,4)dioxepinderivate | |
BR0314352A (pt) | Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6 | |
ATE238981T1 (de) | Antitumorwirkstoffe | |
TWI268280B (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
BR0314363A (pt) | Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6 | |
MX2009002998A (es) | Derivado de pirazolopirimidina. | |
BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
ECSP078015A (es) | 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer | |
MY138124A (en) | Novel farnesyl protein transferase inhibitors as antitumor agents | |
WO2002098399A3 (en) | Cancer treatment method and compositions comprising compounds of the ginger family | |
SV2002000211A (es) | Derivados de higromicina ref. pc10726abcz/bb | |
DK1368336T3 (da) | Thiophensubstituerede aminderivater som GlyT-1-inhibitorer | |
ECSP045249A (es) | "inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES. |
|
B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |